Imagine having a digital copy of your heart that doctors can use to test treatments before actually giving them to you. This tool combines a patient's genetic data and medical scans to predict how their heart will behave. It helps doctors move away from a one-size-fits-all approach to treat heart disease more precisely.
Hypertrophic cardiomyopathy is often treated as a single disease despite diverse phenotypes, leading to suboptimal care and high risks of sudden cardiac death. There is a lack of precise tools to stratify patients and personalize treatment.
A digital-twin platform integrating biophysical and data-driven models, a SMASH_HCM database, and in-vitro cardiac tissue models for drug screening and patient stratification.
If you are a drug discovery firm dealing with high failure rates in cardiac drug trials — this project developed molecular modelling and data-driven tools that screen transcriptomic data to find new candidates through drug repurposing.
If you are a health-tech software provider dealing with the lack of precision in cardiac diagnostics — this project developed a decision support solution using explainable AI that integrates multi-organ biophysical data.
If you are a cardiac clinic dealing with suboptimal care due to treating HCM as a single disease — this project developed a three-level deep phenotyping approach to improve patient stratification and management.
Based on available project data, specific pricing or cost details are not provided, although the project aims to provide a cost-efficient solution for the disease.
Yes, the project serves as a basis for future digital-twin platforms for other cardiac diseases by integrating models and data from various scales and sources.
Based on available project data, the specific licensing terms are not listed, but the project is developing a strategy towards fast regulatory approval.
The platform uses a three-level deep phenotyping approach specifically designed for fast uptake into the clinical workflow for healthcare professionals.
The project runs from 2024-01-01 to 2027-12-31 and includes a pilot clinical trial to validate the stratification and management strategy.
The consortium is well-balanced for commercialization, featuring a 31% industry ratio with 5 industrial partners, including 3 SMEs and one global health-technology corporation. The collaboration involves 16 partners across 8 countries, blending the academic rigor of 9 universities and 2 research centers with the practical application of 3 hospitals, ensuring the tool is clinically validated and market-ready.
Contact TAMPEREEN KORKEAKOULUSAATIO SR in Finland
Contact us to explore licensing opportunities for the SMASH-HCM digital twin platform.
